Takeshi Kajiwara

8PUBLICATIONS
49CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 10, 2025
Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer.

Kanae Inoue, Yoshiaki Nakamura, Bennett Caughey

|Aug 01, 2024
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh

|Jan 09, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.

Yu Sunakawa, Yasutoshi Kuboki, Jun Watanabe

|Nov 14, 2023
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).

Takeshi Kajiwara, Tomohiro Nishina, Riu Yamashita

|Mar 04, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi

|Feb 13, 2023
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.

Kumiko Umemoto, Yu Sunakawa, Makoto Ueno

Pageof 2

Frequent Collaborators

6 joint publications

Takayuki Yoshino

4 joint publications

Yu Sunakawa

3 joint publications

Hideaki Bando

3 joint publications

Hiroki Hara